JP4533185B2 - Solid lipid particle formulation - Google Patents
Solid lipid particle formulation Download PDFInfo
- Publication number
- JP4533185B2 JP4533185B2 JP2005049757A JP2005049757A JP4533185B2 JP 4533185 B2 JP4533185 B2 JP 4533185B2 JP 2005049757 A JP2005049757 A JP 2005049757A JP 2005049757 A JP2005049757 A JP 2005049757A JP 4533185 B2 JP4533185 B2 JP 4533185B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- solid lipid
- lipid particle
- solid
- particle emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000002632 lipids Chemical class 0.000 title claims description 107
- 239000002245 particle Substances 0.000 title claims description 99
- 239000007787 solid Substances 0.000 title claims description 95
- 239000000203 mixture Substances 0.000 title claims description 30
- 238000009472 formulation Methods 0.000 title 1
- 239000000839 emulsion Substances 0.000 claims description 58
- 239000012071 phase Substances 0.000 claims description 30
- 239000008346 aqueous phase Substances 0.000 claims description 23
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000004164 Wax ester Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 235000019386 wax ester Nutrition 0.000 claims description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 8
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 claims description 8
- 229940074979 cetyl palmitate Drugs 0.000 claims description 8
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims description 8
- 229920003169 water-soluble polymer Polymers 0.000 claims description 8
- 235000011837 pasties Nutrition 0.000 claims description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 4
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- 239000004204 candelilla wax Substances 0.000 claims description 2
- 235000013868 candelilla wax Nutrition 0.000 claims description 2
- 229940073532 candelilla wax Drugs 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims description 2
- 235000013869 carnauba wax Nutrition 0.000 claims description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 claims description 2
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 claims description 2
- 229940078812 myristyl myristate Drugs 0.000 claims description 2
- 239000004170 rice bran wax Substances 0.000 claims description 2
- 235000019384 rice bran wax Nutrition 0.000 claims description 2
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 14
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229960000735 docosanol Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- -1 myristic Chemical compound 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- XGFDHKJUZCCPKQ-UHFFFAOYSA-N n-nonadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCCO XGFDHKJUZCCPKQ-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Colloid Chemistry (AREA)
- Medicinal Preparation (AREA)
Description
本発明は、製造が簡便で、安定性の高い固体脂質粒子エマルションに関し、更に詳しくは、成分(A)として室温で固体又はペースト状であるトリグリセライド及び/又はワックスエステルを、成分(B)として炭素数12以上の直鎖で飽和の高級アルコールを、成分(C)としてホスファチジルコリン含量60質量%以上である水素添加リン脂質を含有する脂質成分からなる油相を、水相に分散させて得られることを特徴とする固体脂質粒子エマルションに関する。 The present invention relates to a solid lipid particle emulsion that is easy to produce and highly stable. More specifically, triglyceride and / or wax ester that is solid or pasty at room temperature as component (A) and carbon as component (B). It is obtained by dispersing an oil phase composed of a lipid component containing a hydrogenated phospholipid having a phosphatidylcholine content of 60% by mass or more as a component (C) with a linear and saturated higher alcohol of several 12 or more in an aqueous phase. To a solid lipid particle emulsion.
従来、水と油のように互いに溶解しない液相の一方が、他の一方に微細な液滴として分散したエマルションは、医薬品、医薬部外品、化粧品、食品など幅広い分野で用いられてきた。通常、エマルションは分散相及び連続相の液相の違いにより、水中油型(O/W)エマルションや油中水型(W/O)エマルション、或いはこれらの複合型であるO/W/OエマルションやW/O/Wエマルションなどに分類され、用途に応じて利用されてきた。これらのエマルションは、水相及び油相のいずれも液体状態のものであった。 Conventionally, emulsions in which one of liquid phases that do not dissolve each other, such as water and oil, is dispersed as fine droplets in the other have been used in a wide range of fields such as pharmaceuticals, quasi drugs, cosmetics, and foods. Usually, an emulsion is an oil-in-water (O / W) emulsion, a water-in-oil (W / O) emulsion, or an O / W / O emulsion that is a combination of these depending on the liquid phase of the dispersed phase and the continuous phase. And W / O / W emulsions, etc., have been used depending on the application. In these emulsions, both the aqueous phase and the oil phase were in a liquid state.
近年、上記の他に油相が固体状態であり、これを水相に分散させた脂質粒子エマルションに関する検討が進められている。このような脂質粒子エマルションは、医薬品分野や化粧品分野では、薬剤の吸収性のコントロールなどを目的としたDDS製剤として、また、食品分野では、不安定な物質の安定化や苦味成分のマスキング効果などが期待されている(特許文献1、非特許文献1、2、3参照)。これらにおいては、高圧ホモジナイザーやマイクロチャネル、膜などの特殊な装置を用いた乳化法による脂質粒子エマルションの製造が開示されている。 In recent years, in addition to the above, an oil phase is in a solid state, and studies on lipid particle emulsions in which the oil phase is dispersed in an aqueous phase have been underway. Such lipid particle emulsions are used as DDS preparations for the purpose of controlling the absorbability of drugs in the pharmaceutical field and cosmetic field, and in the food field, the stabilization of unstable substances and the masking effect of bitter components, etc. (See Patent Document 1, Non-Patent Documents 1, 2, and 3). In these, production of a lipid particle emulsion by an emulsification method using a special apparatus such as a high-pressure homogenizer, a microchannel, or a membrane is disclosed.
しかしながら上記の技術では、高価で特殊な装置による製造が必要であり、幅広い分野での応用には不十分であった。また、脂質粒子の界面形成に開示されているリン脂質のうち不飽和を有するものは化学的に不安定であり、また、飽和のリン脂質の場合でもその相転移温度は約50℃付近であり、この相転移温度以上では脂質粒子が不安定化するなどの問題があった。 However, the above technique requires expensive and special equipment and is insufficient for application in a wide range of fields. In addition, phospholipids having unsaturation disclosed in the interface formation of lipid particles are chemically unstable, and even in the case of saturated phospholipids, the phase transition temperature is around 50 ° C. Above this phase transition temperature, there are problems such as destabilization of lipid particles.
上記事情において、特殊な装置を用いることなく容易に固体脂質粒子エマルションの製造が可能であり、且つ安定性の高い固体脂質粒子エマルションが求められていた。即ち、本発明の目的とするところは、容易に製造することが可能であり、安定性に優れる固体脂質粒子エマルションを提供することにある。 In the above circumstances, there has been a demand for a solid lipid particle emulsion that can be easily produced without using a special apparatus and that has high stability. That is, an object of the present invention is to provide a solid lipid particle emulsion that can be easily produced and has excellent stability.
本発明者等は上記事情に鑑み、鋭意研究した結果、特定のリン脂質と高級アルコールを
組み合わせて用いることにより、これらの会合体が相転移温度が、それぞれ単独の場合より数℃から約30℃も上昇することを見出した。そして、これらリン脂質と高級アルコールにトリグリセライドやワックスエステルを加えた脂質成分を油相とし、水相攪拌下に混合すると、リン脂質と高級アルコールが界面を形成し、トリグリセライドやワックスエステルを芯物質とする安定性に優れた固体脂質粒子エマルションが容易に形成されることを見出し、本発明を完成させるに到った。
As a result of diligent research in view of the above circumstances, the present inventors have used a specific phospholipid and a higher alcohol in combination, so that these aggregates have a phase transition temperature of several degrees C. to about 30 ° C. compared to the case where each of them is alone. Also found to rise. When the lipid component obtained by adding triglyceride or wax ester to these phospholipids and higher alcohol is used as an oil phase and mixed with stirring in the aqueous phase, the phospholipid and higher alcohol form an interface, and triglyceride or wax ester is used as the core substance. Thus, the present inventors have found that a solid lipid particle emulsion having excellent stability can be easily formed and completed the present invention.
即ち、本願第1の発明は、下記(A)〜(C)の脂質成分からなる油相を、水相に分散させて得られることを特徴とする固体脂質粒子エマルションにある。
(A)室温で固体又はペースト状であるトリグリセライド及び/又はワックスエステルから選ばれる1種以上。
(B)炭素数12以上の直鎖で飽和の高級アルコールから選ばれる1種以上。
(C)ホスファチジルコリン含量が60質量%以上である水素添加リン脂質から選ばれる1種以上。
That is, the first invention of the present application lies in a solid lipid particle emulsion obtained by dispersing an oil phase comprising the following lipid components (A) to (C) in an aqueous phase.
(A) One or more selected from triglycerides and / or wax esters that are solid or pasty at room temperature.
(B) One or more selected from linear and saturated higher alcohols having 12 or more carbon atoms.
(C) 1 or more types chosen from hydrogenated phospholipid whose phosphatidylcholine content is 60 mass% or more.
本願第2の発明は、成分(B)と成分(C)の質量比(B)/(C)が1/3から50/1の範囲内であり、成分(B)と成分(C)の総量と成分(A)の質量比〔(B)+(C)〕/(A)が1/10から3/1の範囲内であることを特徴とする上記の固体脂質粒子エマルションにある。 In the second invention of this application, the mass ratio (B) / (C) of the component (B) to the component (C) is in the range of 1/3 to 50/1, and the component (B) and the component (C) The solid lipid particle emulsion is characterized in that the mass ratio [(B) + (C)] / (A) of the total amount and the component (A) is in the range of 1/10 to 3/1.
本願第3の発明は、水相が、グリセリン、ジプロピレングリコール、1,3−ブチレングリコール及びポリエチレングリコールからなる群より選ばれる少なくとも1種以上を、更に含有することを特徴とする上記の固体脂質粒子エマルションにある。 According to a third invention of the present application, the solid phase further contains at least one selected from the group consisting of glycerin, dipropylene glycol, 1,3-butylene glycol and polyethylene glycol. In particle emulsion.
本願第4の発明は、水相が、水溶性高分子から選ばれる少なくとも1種以上を、更に含有することを特徴とする上記の固体脂質粒子エマルションにある。 A fourth invention of the present application is the solid lipid particle emulsion described above, wherein the aqueous phase further contains at least one selected from water-soluble polymers.
本願第5の発明は、上記の固体脂質粒子エマルションから、水相を除去することにより得られる固体脂質粒子にある。 5th invention of this application exists in the solid lipid particle obtained by removing an aqueous phase from said solid lipid particle emulsion.
本願第6の発明は、皮膚用又は頭髪用の外用剤であることを特徴とする、上記の固体脂質粒子エマルション又は固体脂質粒子にある。 6th invention of this application exists in said solid lipid particle emulsion or solid lipid particle characterized by being the external preparation for skin or hair.
本願第7の発明は、上記の固体脂質エマルション又は固体脂質粒子を配合することを特徴とする、皮膚用又は頭髪用の外用組成物にある。 7th invention of this application exists in the composition for external use for skin or hair characterized by mix | blending said solid lipid emulsion or solid lipid particle.
成分(A)として室温で固体又はペースト状であるトリグリセライド及び/又はワックステル、成分(B)として炭素数12以上の直鎖で飽和の高級アルコール、成分(C)としてホスファチジルコリン含量が60%以上である水素添加リン脂質からなる脂質成分を、水を含む流動性液体に分散させて得られることを特徴とする本発明の固体脂質粒子エマルションは、容易に製造が可能であり、固体脂質粒子の保存安定性に優れ、外用剤として用いた場合には優れた官能特性を有する。 Component (A) is a triglyceride and / or waxtel that is solid or pasty at room temperature, Component (B) is a linear and saturated higher alcohol having 12 or more carbon atoms, Component (C) has a phosphatidylcholine content of 60% or more. The solid lipid particle emulsion of the present invention, which is obtained by dispersing a lipid component composed of a hydrogenated phospholipid in a fluid liquid containing water, can be easily produced and preserves the solid lipid particles Excellent stability and excellent sensory characteristics when used as an external preparation.
本発明で使用されるトリグリセライドは、脂肪酸とグリセリンのトリエステルを主成分とするものであり、天然の動植物由来又は化学合成などによって得られるものを用いることができる。一方、ワックスエステルは、脂肪酸とアルコールのエステルを主成分とするものであり、天然の動植物由来又は化学合成などによって得られるものを用いることができる。本発明では、前記のトリグリセライド及びワックスエステルのうち、特に室温で固
体又はペースト状のものを、成分(A)として使用する。これらは、室温(20℃)を超える温度域に融点を持ち、特にペースト状のものは室温で完全に液状とならず半固体状である点で、液状のものと区別することができる。
The triglyceride used in the present invention is mainly composed of a fatty acid and a triester of glycerin, and those derived from natural animals and plants or obtained by chemical synthesis can be used. On the other hand, the wax ester is composed mainly of fatty acid and alcohol esters, and those derived from natural animals and plants or obtained by chemical synthesis or the like can be used. In the present invention, among the above-mentioned triglycerides and wax esters, those which are solid or pasty at room temperature are used as the component (A). These have a melting point in a temperature range exceeding room temperature (20 ° C.), and in particular, pastes can be distinguished from liquids in that they are not completely liquid at room temperature but are semi-solid.
本発明における成分(A)としては、上記の要件を満たすトリグリセライド又はワックスエステルをそれぞれ単独で使用しても、2種以上を混合して使用しても良い。また単独では固体又はペースト状でなくても、他のものと混合した場合、混合物として固体又はペースト状の性状を呈するものであれば、本願成分(A)に該当するものとして使用が可能である。 As a component (A) in this invention, the triglyceride or wax ester which satisfy | fills said requirements may be used individually, respectively, or 2 or more types may be mixed and used for it. Moreover, even if it is not solid or pasty alone, it can be used as a component corresponding to the present component (A) as long as it exhibits solid or pasty properties as a mixture when mixed with other things. .
具体的には、トリグリセライドとしては、トリミリスチン酸グリセリル、トリパルミチン酸グリセリル、トリステアリン酸グリセリル、トリベヘン酸グリセリル、トリ(カプリル・カプリン・ミリスチン・ステアリン)酸グリセリル、パーム油、ヤシ油、牛脂、硬化油などを挙げることができる。またワックスエステルとしては、ミリスチン酸ミリスチル、ミリスチン酸セチル、パルミチン酸セチル、ステアリン酸セチル、ミツロウ、カルナバロウ、キャンデリラロウ、コメヌカロウなどを挙げることができる。 Specific examples of triglycerides include glyceryl trimyristate, glyceryl tripalmitate, glyceryl tristearate, glyceryl tribehenate, glyceryl tri (capryl, caprin, myristic, stearate), palm oil, coconut oil, beef tallow, cured An oil etc. can be mentioned. Examples of the wax ester include myristyl myristate, cetyl myristate, cetyl palmitate, cetyl stearate, beeswax, carnauba wax, candelilla wax, rice bran wax and the like.
本発明で成分(B)として使用される高級アルコールは、炭素数12以上の直鎖で飽和の高級アルコールであり、動植物由来又は化学合成のものどちらでも使用可能である。これら高級アルコールは単独で用いることも、2種以上を混合して用いることもできる。 The higher alcohol used as the component (B) in the present invention is a linear and saturated higher alcohol having 12 or more carbon atoms, and can be derived from animals or plants or chemically synthesized. These higher alcohols can be used alone or in combination of two or more.
本発明で使用される高級アルコールとしては、ドデカノール、トリデカノール、テトラデカノール、ペンタデカノール、ヘキサデカノール、ヘプタデカノール、オクタデカノール、ノナデカノール、イコサノール、ヘンイコサノール、ドコサノール、オクタコサノール、ドトリアコンタノールなどを挙げることができる。 Examples of the higher alcohol used in the present invention include dodecanol, tridecanol, tetradecanol, pentadecanol, hexadecanol, heptadecanol, octadecanol, nonadecanol, icosanol, heicosanol, docosanol, octacosanol, dotoriacontanol and the like. Can be mentioned.
本発明の成分(C)のリン脂質としては、ホスファチジルコリン含量が60質量%以上であり、水素添加した水素添加リン脂質を使用する。ホスファチジルコリン以外のリン脂質成分としては、ホスファチジン酸、ホスファチジルセリン、ホスファチジルエタノールアミン、ホスファチジルイノシトール、ホスファチジルグリセロールなどが挙げられる。本発明で使用されるリン脂質としては、天然の動植物由来のリン脂質、例えば卵黄由来又は大豆由来のリン脂質を水素添加したものが挙げられる。また、化学合成したものも同様に使用することが可能である。 As the phospholipid of the component (C) of the present invention, a hydrogenated phospholipid having a phosphatidylcholine content of 60% by mass or more and using hydrogenation is used. Examples of phospholipid components other than phosphatidylcholine include phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylglycerol. Examples of the phospholipid used in the present invention include phospholipids derived from natural animals and plants, such as those obtained by hydrogenating egg yolk-derived or soybean-derived phospholipids. Moreover, what was chemically synthesized can also be used similarly.
本発明の固体脂質粒子を構成する(A)〜(C)各脂質成分の組成比としては、成分(B)と成分(C)の質量比(B)/(C)が1/3から50/1の範囲内であることが好ましく、さらに好ましくは1/2から20/1の範囲内である。
また、成分(B)と成分(C)の総量と成分(A)の質量比〔(B)+(C)〕/(A)が1/10から3/1の範囲内であることが好ましく、さらに好ましくは1/2から35/1の範囲内である。これらの範囲内だと固体脂質粒子エマルションの調製がより容易であり、また固体脂質粒子の安定性にも特に優れる。
As the composition ratio of each lipid component (A) to (C) constituting the solid lipid particle of the present invention, the mass ratio (B) / (C) of the component (B) to the component (C) is from 1/3 to 50. Is preferably in the range of 1/2, more preferably in the range of 1/2 to 20/1.
Further, the mass ratio [(B) + (C)] / (A) of the total amount of component (B) and component (C) to component (A) is preferably in the range of 1/10 to 3/1. More preferably, it is in the range of 1/2 to 35/1. Within these ranges, the preparation of the solid lipid particle emulsion is easier and the stability of the solid lipid particles is particularly excellent.
本発明の固体脂質粒子エマルションにおける油相である上記成分(A)から(C)の脂質成分には、簡便に安定な固体脂質粒子エマルションが製造できるという本願発明の効果を損なわない範囲で、油溶性の各種成分を配合することが可能である。 The lipid components (A) to (C), which are the oil phase in the solid lipid particle emulsion of the present invention, can be used within a range that does not impair the effect of the present invention that a stable solid lipid particle emulsion can be easily produced. It is possible to mix various soluble components.
本発明の固体脂質粒子エマルションにおける連続相である水相は、実質的に水からなる液相であるが、必要に応じて、固体脂質粒子エマルションの調製に影響を及ぼさない範囲で、水と相溶性を有する他の溶媒や水溶性の各種成分を配合することが可能である。 The aqueous phase, which is a continuous phase in the solid lipid particle emulsion of the present invention, is a liquid phase consisting essentially of water. However, if necessary, the aqueous phase is in a range that does not affect the preparation of the solid lipid particle emulsion. It is possible to mix other soluble solvents and various water-soluble components.
本発明では、水相に、更にグリセリン、ジプロピレングリコール、1,3−ブチレングリコール及びポリエチレングリコールからなる群より選ばれる1種以上を含有させると、エマルションの安定性、また外用組成物としての官能特性が向上するため好ましい。 In the present invention, when the aqueous phase further contains at least one selected from the group consisting of glycerin, dipropylene glycol, 1,3-butylene glycol and polyethylene glycol, the stability of the emulsion and the functionality as a composition for external use. This is preferable because the characteristics are improved.
また、本発明では、水相に、更に水溶性高分子をから選ばれる1種以上を含有させると、エマルションの安定性、また外用組成物としての官能特性が向上するため好ましい。 In the present invention, it is preferable that the water phase further contains at least one water-soluble polymer selected from water-soluble polymers because the stability of the emulsion and the sensory characteristics as an external composition are improved.
前記水溶性高分子としては、天然水溶性高分子、天然水溶性高分子誘導体、合成水溶性高分子などを、単独又は2種以上を混合して使用することが可能である。具体的には、カラギーナン、アルギン酸、寒天、グアーガム、デンプン、ペクチン、大豆タンパク、ゼラチン、アルブミン、カゼイン、ヒアルロン酸、キサンタンガム、メチルセルロース、エチルセルロース、ヒドロキシプロピルメチルセルロース、カルボキシビニルポリマー、アクリル酸・メタクリル酸アルキル共重合体、ポリアクリル酸アミド、ポリビニルアルコール、ポリビニルピロリドンなどを挙げることができる。 As the water-soluble polymer, natural water-soluble polymers, natural water-soluble polymer derivatives, synthetic water-soluble polymers and the like can be used alone or in admixture of two or more. Specifically, carrageenan, alginic acid, agar, guar gum, starch, pectin, soy protein, gelatin, albumin, casein, hyaluronic acid, xanthan gum, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, carboxyvinyl polymer, acrylic acid / alkyl methacrylate A polymer, polyacrylic acid amide, polyvinyl alcohol, polyvinyl pyrrolidone, etc. can be mentioned.
本発明の固体脂質粒子エマルションは、油相である脂質成分を加温溶解した後に、同温度以上に加温した水相を攪拌させた中に、前記油相を添加、分散させ、その後冷却を行うことにより製造することができる。水相の攪拌には特殊な装置を用いる必要はなく、加温及び攪拌が可能であれば、公知の任意の装置、例えばマグネチックスターラーやホモミキサーなどで製造することができる。また、簡便な攪拌分散による製造ではなく、高圧ホモジナイザーやマイクロチャネル、膜などの特殊な装置を用いて製造することも可能である。 In the solid lipid particle emulsion of the present invention, the lipid component that is the oil phase is heated and dissolved, and then the oil phase is added and dispersed while stirring the aqueous phase heated to the same temperature or higher, and then cooled. It can be manufactured by doing. It is not necessary to use a special apparatus for stirring the aqueous phase, and it can be produced by any known apparatus such as a magnetic stirrer or a homomixer as long as heating and stirring are possible. Moreover, it is also possible to produce using a special apparatus such as a high-pressure homogenizer, a microchannel, or a membrane, instead of simple stirring and dispersion.
本発明の特定の脂質成分を用いた場合に、固体脂質粒子エマルションが簡便かつ安定的に製造される詳細なメカニズムは不明であるが、リン脂質に高級アルコールを組み合わせると相転移温度が上昇することが確認されており、これが固体脂質粒子の界面の安定性を高めるのが、その理由のひとつであると考えられる。 When the specific lipid component of the present invention is used, the detailed mechanism by which a solid lipid particle emulsion is easily and stably produced is unknown, but the phase transition temperature increases when a higher alcohol is combined with phospholipid. This is considered to be one of the reasons for enhancing the stability of the solid lipid particle interface.
上記の固体脂質粒子エマルションの製造において、固体脂質粒子を構成する脂質成分の含有量を固体脂質粒子エマルション全体に対して30質量%以下とすると、水相に対する脂質成分の分散がより容易であると同時に、外用組成物と使用した場合の官能特性にも優れるため好ましい。30質量%を超えてしまうと、分散の効率が悪くなり、攪拌条件にもよるが、場合によっては分散不能となることもある。 In the production of the solid lipid particle emulsion, when the content of the lipid component constituting the solid lipid particle is 30% by mass or less with respect to the entire solid lipid particle emulsion, the dispersion of the lipid component in the aqueous phase is easier. At the same time, it is preferable because it has excellent sensory characteristics when used with an external composition. If it exceeds 30% by mass, the efficiency of dispersion deteriorates, and depending on the stirring conditions, it may become impossible to disperse in some cases.
本発明の固体脂質粒子は、上記の手法により得られた固体脂質粒子エマルションから、流動性液体を除去することにより製造することが可能である。流動性液体の除去には、公知の任意の手法を用いることが可能である。例えば、遠心分離、膜濾過、凍結乾燥などを挙げることができる。 The solid lipid particles of the present invention can be produced by removing the fluid liquid from the solid lipid particle emulsion obtained by the above method. Any known technique can be used to remove the fluid liquid. For example, centrifugation, membrane filtration, lyophilization and the like can be mentioned.
本発明に係る固体脂質粒子エマルション又は固体脂質粒子は、外用剤として皮膚や毛髪などの体表面に適用することができ、独特の官能特性を賦与することが可能である。また、本発明の固体脂質粒子エマルション又は固体脂質粒子は、各種の皮膚用及び毛髪用の外用組成物に配合成分として配合することもでき、これら外用組成物に独特の官能特性を賦与することが可能である。 The solid lipid particle emulsion or solid lipid particle according to the present invention can be applied to a body surface such as skin or hair as an external preparation and can impart unique sensory characteristics. In addition, the solid lipid particle emulsion or solid lipid particle of the present invention can be blended as a blending component in various external compositions for skin and hair, and can impart unique sensory characteristics to these external compositions. Is possible.
本発明に係る固体脂質粒子エマルション又は固体脂質粒子を配合した外用組成物には、必要に応じて、化粧品、医薬部外品、医薬品、食品等に通常配合される成分を配合することができる。すなわち、具体的成分として、生理学的薬効成分、油脂類、色素、香料、防腐剤、界面活性剤、顔料、酸化防止剤、キレート剤、紫外線吸収剤、紫外線散乱剤、無機塩類、糖類、塩類、ビタミン類、植物抽出液等を挙げることができる。 In the external composition containing the solid lipid particle emulsion or the solid lipid particles according to the present invention, components that are usually added to cosmetics, quasi drugs, pharmaceuticals, foods and the like can be added as necessary. That is, as specific ingredients, physiological medicinal ingredients, fats and oils, dyes, fragrances, preservatives, surfactants, pigments, antioxidants, chelating agents, ultraviolet absorbers, ultraviolet scattering agents, inorganic salts, saccharides, salts, Vitamins, plant extracts and the like can be mentioned.
以下、本発明を実施例及び比較例を挙げて更に詳しく説明するが、本発明はこれらの実施例に限定されるわけではない。 EXAMPLES Hereinafter, although an Example and a comparative example are given and this invention is demonstrated in more detail, this invention is not necessarily limited to these Examples.
実施例1
セチルパルミテート5g、ヘキサデカノール1g、水素添加大豆リン脂質(ホスファチジルコリン含量90質量%以上、以下、含量に応じて「PC90」等と略記)0.5gを均一に加温溶解し油相を得た。次いで、予め80℃に加温した精製水93.5gをマグネチックスターラーにて400回転/分で攪拌させた中に、油相を徐々に加え乳化を行った。この乳化液を室温まで冷却し、本発明の固体脂質粒子エマルションを得た。得られた固体脂質粒子エマルションを偏光顕微鏡で観察し、粒子径約100から500μmの球状で結晶質の固体脂質粒子の生成を確認した(図1)。この固体脂質粒子エマルションを40℃、1ヶ月の条件にて保存し、固体脂質粒子の安定性を偏光顕微鏡により確認したところ、固体脂質粒子相のクリーミングは認められたものの、固体脂質粒子の崩壊や合一は認められず、また、結晶状態を保っており安定であった。
Example 1
5 g of cetyl palmitate, 1 g of hexadecanol, and 0.5 g of hydrogenated soybean phospholipid (phosphatidylcholine content of 90 mass% or more, hereinafter abbreviated as “PC90” or the like depending on the content) are uniformly heated and dissolved to obtain an oil phase. It was. Next, 93.5 g of purified water preheated to 80 ° C. was stirred at 400 rpm with a magnetic stirrer, and the oil phase was gradually added to emulsify. This emulsion was cooled to room temperature to obtain a solid lipid particle emulsion of the present invention. The obtained solid lipid particle emulsion was observed with a polarizing microscope, and it was confirmed that spherical and crystalline solid lipid particles having a particle diameter of about 100 to 500 μm were formed (FIG. 1). This solid lipid particle emulsion was stored at 40 ° C. for one month, and the stability of the solid lipid particles was confirmed by a polarizing microscope. Coherence was not recognized, and the crystal state was maintained and was stable.
(示差走査熱分析)
実施例1で作製した固体脂質粒子エマルションをDSC(示差走査熱分析)測定を行い、相転移温度の分析を行った。また、実施例1で使用した各脂質成分、並びにそれらから選ばれる2種による混合脂質についても、比較として分析を行った。分析は、示差走査熱量計(DSC6200、エスアイアイ・ナノテクノロジー社製)を用い、5℃/分の昇温条件にて行った。尚、実施例1の固体脂質粒子エマルションについてはそのままを分析試料としたが、それ以外の脂質試料については、脂質成分に対して7倍重量の水を加え、一度相転移温度以上に昇温して十分に水和させた後に急冷したものを分析試料として使用した。
(Differential scanning thermal analysis)
The solid lipid particle emulsion prepared in Example 1 was subjected to DSC (Differential Scanning Calorimetry) measurement, and the phase transition temperature was analyzed. Moreover, it analyzed as a comparison also about each lipid component used in Example 1, and the mixed lipid by 2 types chosen from them. The analysis was performed using a differential scanning calorimeter (DSC6200, manufactured by SII Nano Technology) under a temperature rising condition of 5 ° C./min. The solid lipid particle emulsion of Example 1 was used as an analysis sample as it was, but for the other lipid samples, 7 times the weight of water was added to the lipid component, and the temperature was once raised to the phase transition temperature or higher. The sample was quenched after being sufficiently hydrated and used as an analytical sample.
分析結果を表1に示す。表中の数字はDSC曲線のピークトップの温度を示し、2種混合の脂質に関しては、種々の混合比率で測定したうち、最も高いピークトップの温度を示す。実施例1で使用した各脂質成分単独の場合、いずれも52℃付近が相転移温度であった。一方、2種の脂質を混合した系では、ヘキサデカノールと水素添加大豆リン脂質(PC90)を混合した場合に、相転移温度が20℃近くも上昇するという特異な現象が確認された。 The analysis results are shown in Table 1. The numbers in the table indicate the peak top temperature of the DSC curve, and for the two mixtures of lipids, the highest peak top temperature is measured among the various mixing ratios. In the case of each lipid component used alone in Example 1, the phase transition temperature was around 52 ° C. in all cases. On the other hand, in the system in which two kinds of lipids were mixed, a unique phenomenon was observed in which the phase transition temperature rose as close as 20 ° C. when hexadecanol and hydrogenated soybean phospholipid (PC90) were mixed.
(表1)
―――――――――――――――――――――――
試 料 (℃)
―――――――――――――――――――――――
(a)セチルパルミテート 52.2
(b)ヘキサデカノール 52.5
(c)水素添加大豆リン脂質(PC90) 52.1
(a)と(b)の混合脂質 48.1
(a)と(c)の混合脂質 52.1
(b)と(c)の混合脂質 70.6
−−−−−−−−−−−−−−−−−−−−−−−
実施例1の固体脂質粒子 ピーク1 31.6
ピーク2 45.4
ピーク3 48.6
ピーク4 68.7
―――――――――――――――――――――――
(Table 1)
―――――――――――――――――――――――
Sample (℃)
―――――――――――――――――――――――
(a) Cetyl palmitate 52.2
(b) Hexadecanol 52.5
(c) Hydrogenated soybean phospholipid (PC90) 52.1
Mixed lipid of (a) and (b) 48.1
Mixed lipid of (a) and (c) 52.1
Mixed lipids of (b) and (c) 70.6
-----------------------
Solid lipid particles of Example 1 Peak 1 31.6
Peak 2 45.4
Peak 3 48.6
Peak 4 68.7
―――――――――――――――――――――――
実施例1の固体脂質粒子エマルションの場合のDSC曲線を図2に示す。図に示すように、ピーク1からピーク4の4つのピークが検出された。表1に示すように、これらのうちピーク4の温度は、ヘキサデカノールと水素添加大豆リン脂質(PC90)の混合脂質系のピーク温度とほぼ一致し、ピーク3の温度は、セチルパルミテートとヘキサデカノールの混合脂質系のピーク温度とほぼ一致した。これらの結果及び構成成分の極性などの物性から判断すると、実施例1の固体脂質粒子は、ヘキサデカノールと水素添加大豆リン脂質(PC90)が界面を形成し、セチルパルミテート及び過剰なヘキサデカノールを芯物質とする構造となっていると考えられる。即ち、本発明で開示する特定成分の特定割合からなる組成とすることにより、それぞれの構成成分単独の場合よりも高い温度で界面に水和固体が形成され、製造が容易で熱安定性に優れる固体脂質エマルションが形成されることが示唆された。 The DSC curve for the solid lipid particle emulsion of Example 1 is shown in FIG. As shown in the figure, four peaks from peak 1 to peak 4 were detected. As shown in Table 1, among these, the temperature of peak 4 almost coincides with the peak temperature of the mixed lipid system of hexadecanol and hydrogenated soybean phospholipid (PC90), and the temperature of peak 3 is cetyl palmitate and It almost coincided with the peak temperature of the mixed lipid system of hexadecanol. Judging from these results and physical properties such as polarities of the constituent components, in the solid lipid particles of Example 1, hexadecanol and hydrogenated soybean phospholipid (PC90) form an interface, and cetyl palmitate and excess hexadeca It is thought that it has a structure with a knoll as a core substance. That is, by using a composition composed of a specific proportion of the specific component disclosed in the present invention, a hydrated solid is formed at the interface at a higher temperature than in the case of each component alone, and it is easy to produce and has excellent thermal stability. It was suggested that a solid lipid emulsion was formed.
実施例2
実施例1と同様の組成及び製造法にて固体脂質粒子エマルションを製造した後に、水を濾別し、凍結乾燥を行い、本発明の固体脂質粒子の粉末を得た。得られた固体脂質粒子を偏光顕微鏡で観察し、粒子径が約100から500μmである球状で結晶質の固体脂質粒子を確認した。この固体脂質粒子の粉末を、実施例1と同様40℃、1ヶ月の条件にて保存し、その安定性を偏光顕微鏡で確認したところ、固体脂質粒子の崩壊や合一は認められず、また、結晶状態を保っており安定であった。
Example 2
After producing a solid lipid particle emulsion by the same composition and production method as in Example 1, water was filtered off and freeze-dried to obtain solid lipid particle powder of the present invention. The obtained solid lipid particles were observed with a polarizing microscope, and spherical and crystalline solid lipid particles having a particle diameter of about 100 to 500 μm were confirmed. This solid lipid particle powder was stored at 40 ° C. for one month as in Example 1, and its stability was confirmed with a polarizing microscope. The crystal state was maintained and was stable.
実施例3、比較例1〜3
下記表2の組成からなる本発明の固体脂質粒子(実施例3)及び比較例1〜3の固体粒子を、実施例1と同様の方法にてエマルションを製造し、実施例2と同様の方法により水を除去することにより製造した。また、粒子の生成を偏光顕微鏡により、生成した固体脂質粒子の安定性を、実施例1と同様の40℃、1ヶ月の保存条件にて評価した。尚、表中の組成における配合量は質量%である。
Example 3, Comparative Examples 1-3
The solid lipid particles of the present invention (Example 3) having the composition shown in Table 2 below and the solid particles of Comparative Examples 1 to 3 were produced in the same manner as in Example 1, and the same method as in Example 2. By removing water. Moreover, the production | generation of particle | grains was evaluated with the same 40 degreeC and 1 month storage conditions as Example 1 for the stability of the produced | generated solid lipid particle | grains with the polarization microscope. In addition, the compounding quantity in the composition in a table | surface is the mass%.
(表2)
―――――――――――――――――――――――――――――――――――――――
実施例 比較例 比較例 比較例
成分名 3 1 2 3
―――――――――――――――――――――――――――――――――――――――
(1)トリステアリン酸グリセリル 15.0 − 15.0 15.0
(2)オクタデカノール 10.0 10.0 − 10.0
(3)水素添加卵黄リン脂質 2.0 2.0 2.0 −
(PC70)
(4)精製水 残余 残余 残余 残余
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
粒子の生成 球状固体粒子 生成せず 非晶質粒子 生成せず
保存安定性 安定 − 合一及び凝集 −
―――――――――――――――――――――――――――――――――――――――
(Table 2)
―――――――――――――――――――――――――――――――――――――――
Examples Comparative Examples Comparative Examples Comparative Examples Ingredient names 3 1 2 3
―――――――――――――――――――――――――――――――――――――――
(1) Glyceryl tristearate 15.0-15.0 15.0
(2) Octadecanol 10.0 10.0-10.0
(3) Hydrogenated egg yolk phospholipids 2.0 2.0 2.0 −
(PC70)
(4) Purified water Residual Residue Residual Residue Residue --------------------------------
Generation of particles Spherical solid particles Not generated Amorphous particles Not generated Storage stability Stable − Coalescence and aggregation −
―――――――――――――――――――――――――――――――――――――――
表2に記載の如く、実施例3の固体脂質粒子は、球状の固体脂質粒子を形成し、その保存安定性にも優れていた。しかしながら、本発明の要件を満たさない比較例1及び比較例3の組成では、球状の固体粒子を生成しなかった。また、比較例2では、粒子を生成したものの、その粒子は非晶質であり、安定性に劣るものであった。 As shown in Table 2, the solid lipid particles of Example 3 formed spherical solid lipid particles and were excellent in storage stability. However, the compositions of Comparative Examples 1 and 3 that did not satisfy the requirements of the present invention did not produce spherical solid particles. In Comparative Example 2, although particles were generated, the particles were amorphous and inferior in stability.
実施例4〜7
下記表3の組成からなる本発明の固体脂質粒子エマルションを製造した。製造方法は、
油相成分を均一に混合溶解させた後に、予め混合し80℃に加温した水相に攪拌下で加え、ホモミキサーを用いて5000回転/分にて乳化を行い、攪拌下で室温まで冷却させた。尚、表中の組成における配合量は質量%である。
Examples 4-7
The solid lipid particle emulsion of the present invention having the composition shown in Table 3 below was produced. The manufacturing method is
After the oil phase components are uniformly mixed and dissolved, they are added to the aqueous phase that has been premixed and heated to 80 ° C. with stirring. The mixture is emulsified with a homomixer at 5000 rpm and cooled to room temperature with stirring. I let you. In addition, the compounding quantity in the composition in a table | surface is the mass%.
(表3)
―――――――――――――――――――――――――――――――――――――――
実施例 実施例 実施例 実施例
成分名 4 5 6 7
―――――――――――――――――――――――――――――――――――――――
(油相成分)
(1)トリパルミチン酸グリセリル 8.0 8.0 8.0 8.0
(2)パルミチン酸セチル 2.0 2.0 2.0 2.0
(3)セチルアルコール(*) 1.0 1.0 1.0 1.0
(4)水素添加大豆リン脂質 0.3 0.5 1.0 1.5
(PC90)
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
(水相成分)
(5)グリセリン 5.0 5.0 5.0 5.0
(6)フェノキシエタノール 0.1 0.1 0.1 0.1
(7)カルボキシビニルポリマー 0.1 0.1 0.1 0.1
(8)水酸化カリウム 0.03 0.03 0.03 0.03
(9)精製水 残余 残余 残余 残余
―――――――――――――――――――――――――――――――――――――――
* ヘキサデカノールを主成分とするオクタデカノール、テトラデカノールなどとの混合物
(Table 3)
―――――――――――――――――――――――――――――――――――――――
Examples Examples Examples Examples Ingredient names 4 5 6 7
―――――――――――――――――――――――――――――――――――――――
(Oil phase component)
(1) Glyceryl tripalmitate 8.0 8.0 8.0 8.0
(2) Cetyl palmitate 2.0 2.0 2.0 2.0
(3) Cetyl alcohol (*) 1.0 1.0 1.0 1.0
(4) Hydrogenated soybean phospholipid 0.3 0.5 1.0 1.5
(PC90)
------------------------------------
(Aqueous phase component)
(5) Glycerin 5.0 5.0 5.0 5.0
(6) Phenoxyethanol 0.1 0.1 0.1 0.1
(7) Carboxyvinyl polymer 0.1 0.1 0.1 0.1
(8) Potassium hydroxide 0.03 0.03 0.03 0.03
(9) Purified water Residue Residue Residue Residue Residue ---------------
* Mixture with octadecanol, tetradecanol, etc. mainly composed of hexadecanol
得られた固体脂質粒子エマルションを実施例1と同様の手法により評価したところ、粒子径約20から100μmである球状の固体脂質粒子の生成を確認し、保存安定性にも優れるものであった。また、クリーミングなどの現象も認められず製剤としての安定性にも優れるものであった。 When the obtained solid lipid particle emulsion was evaluated by the same method as in Example 1, it was confirmed that spherical solid lipid particles having a particle diameter of about 20 to 100 μm were formed, and the storage stability was excellent. Further, no phenomenon such as creaming was observed, and the stability as a preparation was excellent.
下記表4の組成からなる本発明の固体脂質粒子エマルションを製造した。製造方法は、油相成分を均一に混合溶解した後に、予め混合し80℃に加温した水相成分に攪拌下で加え、ホモミキサーを用いて5000回転/分にて乳化を行い、攪拌下で室温まで冷却して製造した。尚、表中の組成における配合量は質量%である。 The solid lipid particle emulsion of the present invention having the composition shown in Table 4 below was produced. In the production method, the oil phase component is uniformly mixed and dissolved, then added to the aqueous phase component previously mixed and heated to 80 ° C. with stirring, emulsified at 5000 rpm with a homomixer, and stirred. And cooled to room temperature. In addition, the compounding quantity in the composition in a table | surface is the mass%.
(表4)
―――――――――――――――――――――――――――――――――――――――
実施例 実施例 実施例 実施例
成分名 8 9 10 11
―――――――――――――――――――――――――――――――――――――――
(油相成分)
(1)トリパルミチン酸グリセリル 8.0 8.0 8.0 8.0
(2)パルミチン酸セチル 2.0 2.0 2.0 2.0
(3)セチルアルコール(*) 5.0 5.0 5.0 5.0
(4)ベヘニルアルコール(**) − 3.0 5.0 10.0
(5)水素添加大豆リン脂質 1.0 1.0 1.0 1.0
(PC90)
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
(水相成分)
(6)グリセリン 5.0 5.0 5.0 5.0
(7)フェノキシエタノール 0.1 0.1 0.1 0.1
(8)カルボキシビニルポリマー 0.1 0.1 0.1 0.1
(9)水酸化カリウム 0.03 0.03 0.03 0.03
(10)精製水 残余 残余 残余 残余
―――――――――――――――――――――――――――――――――――――――
* ヘキサデカノールを主成分とするオクタデカノール、テトラデカノールなどとの混合物
** ドコサノールを主成分とするオクタデカノール、ヘキサデカノールなどとの混合物
(Table 4)
―――――――――――――――――――――――――――――――――――――――
Examples Examples Examples Examples Ingredients 8 9 10 11
―――――――――――――――――――――――――――――――――――――――
(Oil phase component)
(1) Glyceryl tripalmitate 8.0 8.0 8.0 8.0
(2) Cetyl palmitate 2.0 2.0 2.0 2.0
(3) Cetyl alcohol (*) 5.0 5.0 5.0 5.0
(4) Behenyl alcohol (**) -3.0 5.0 5.0
(5) Hydrogenated soybean phospholipid 1.0 1.0 1.0 1.0
(PC90)
------------------------------------
(Aqueous phase component)
(6) Glycerin 5.0 5.0 5.0 5.0
(7) Phenoxyethanol 0.1 0.1 0.1 0.1
(8) Carboxyvinyl polymer 0.1 0.1 0.1 0.1
(9) Potassium hydroxide 0.03 0.03 0.03 0.03
(10) Purified water Residue Residue Residue Residue Residue ---------------
* Mixture with octadecanol, tetradecanol, etc. mainly composed of hexadecanol
** Mixture with octadecanol, hexadecanol, etc. based on docosanol
得られた固体脂質粒子エマルションを実施例1と同様の手法により評価したところ、粒子径約20から100μmである球状の固体脂質粒子の生成を確認し、保存安定性にも優れるものであった。また、クリーミングなどの現象も認められず製剤としての安定性にも優れるものであった。 When the obtained solid lipid particle emulsion was evaluated by the same method as in Example 1, it was confirmed that spherical solid lipid particles having a particle diameter of about 20 to 100 μm were formed, and the storage stability was excellent. Further, no phenomenon such as creaming was observed, and the stability as a preparation was excellent.
実施例12
下表5の組成からなる本発明の固体脂質粒子エマルションを製造した。製造方法は、油相成分を均一に混合溶解させた後に、予め混合し80℃に加温した水相に攪拌下で加え、ホモミキサーを用いて5000回転/分にて乳化を行い、攪拌下で室温まで冷却させた。
Example 12
The solid lipid particle emulsion of the present invention having the composition shown in Table 5 below was produced. In the production method, the oil phase components are uniformly mixed and dissolved, and then added to the aqueous phase premixed and heated to 80 ° C. with stirring. The mixture is emulsified with a homomixer at 5000 rpm and stirred. And cooled to room temperature.
(表5)
――――――――――――――――――――――――
成分名 質量%
――――――――――――――――――――――――
(油相成分)
(1) トリ(カプリル・カプリン 8.0
・ミリスチン・ステアリン)酸グリセリル
(2) ミツロウ 4.0
(3) ベヘニルアルコール 6.0
(4) ステアリルアルコール 2.0
(5) 水素添加大豆リン脂質(PC90) 0.7
−−−−−−−−−−−−−−−−−−−−−−−
(水相成分)
(6) ジプロピレングリコール 3.0
(7) 1,3−ブチレングリコール 3.0
(8) ヒアルロン酸ナトリウム 0.1
(9) アクリル酸・メタクリル酸 0.1
アルキル共重合体
(10)水酸化カリウム 0.02
(11)メチルパラベン 0.1
(12)エデト酸三ナトリウム 0.02
(13)精製水 残余
――――――――――――――――――――――――
(Table 5)
――――――――――――――――――――――――
Ingredient name Mass%
――――――――――――――――――――――――
(Oil phase component)
(1) Tori (Capril Caprin 8.0
・ Myristine stearic acid glyceryl
(2) Beeslow 4.0
(3) Behenyl alcohol 6.0
(4) Stearyl alcohol 2.0
(5) Hydrogenated soybean phospholipid (PC90) 0.7
-----------------------
(Aqueous phase component)
(6) Dipropylene glycol 3.0
(7) 1,3-butylene glycol 3.0
(8) Sodium hyaluronate 0.1
(9) Acrylic acid / methacrylic acid 0.1
Alkyl copolymer
(10) Potassium hydroxide 0.02
(11) Methylparaben 0.1
(12) edetate trisodium 0.02
(13) Purified water residue ――――――――――――――――――――――――
得られた固体脂質粒子エマルションを偏光顕微鏡により観察し、粒子径20から50μmである球状の固体脂質粒子の生成を確認した。得られた固体脂質粒子エマルションを40℃、1ヶ月の条件で保存し、安定性を確認したところ、凝集や合一は認められず、安定性に優れるものであった。また、得られた組成物に関し官能評価を行ったところ、のびが良く、保湿感に優れた外用組成物であった。 The obtained solid lipid particle emulsion was observed with a polarizing microscope, and formation of spherical solid lipid particles having a particle diameter of 20 to 50 μm was confirmed. The obtained solid lipid particle emulsion was stored at 40 ° C. for 1 month and confirmed for stability. As a result, no aggregation or coalescence was observed, and the stability was excellent. Moreover, when sensory evaluation was performed regarding the obtained composition, it was a composition for external use having good stretch and excellent moisturizing feeling.
本発明の固体脂質粒子エマルション並びに固体脂質粒子は、容易に製造することができ、安定性にも優れることから、化粧品、医薬部外品、医薬品、食品に適用することができる。 Since the solid lipid particle emulsion and the solid lipid particle of the present invention can be easily produced and have excellent stability, they can be applied to cosmetics, quasi drugs, pharmaceuticals, and foods.
Claims (6)
(A)室温で固体又はペースト状であるトリグリセライド、並びにミリスチン酸ミリスチル、ミリスチン酸セチル、パルミチン酸セチル、ステアリン酸セチル、ミツロウ、カルナバロウ、キャンデリラロウ及びコメヌカロウから選ばれるワックスエステルから選ばれる1種以上。
(B)炭素数12以上の直鎖で飽和の高級アルコールから選ばれる1種以上。
(C)ホスファチジルコリン含量が60質量%以上である水素添加リン脂質から選ばれる1種以上。 An oil phase composed of the lipid components (A) to (C) below is obtained by dispersing in an aqueous phase, and the mass ratio (B) / (C) of the component (B) to the component (C) is from 1/3. 50/1, and the mass ratio of the total amount of component (B) and component (C) to component (A) [(B) + (C)] / (A) is from 1/10 to 3/1. solid lipid particles the emulsion, characterized in range der Rukoto ((a) a phospholipid, (b) a nonionic surfactant, (c) a higher alcohol, (d) an oil, (e) a polyhydric alcohol and ( f) It contains water, the content of component (d) is 1 to 30% by mass, the component (d) contains 40% by mass or more of solid oil and / or paste oil, and component (a) And the total content of component (b) and the content ratio of component (d) is 2: 1 to 1:10 by mass ratio, and the particle size of the emulsified droplets is 1 μm or less. Except that an oil-in-water emulsified cosmetic.).
(A) One or more triglycerides that are solid or pasty at room temperature and one or more wax esters selected from myristyl myristate, cetyl myristate, cetyl palmitate, cetyl stearate, beeswax, carnauba wax, candelilla wax and rice bran wax .
(B) One or more selected from linear and saturated higher alcohols having 12 or more carbon atoms.
(C) 1 or more types chosen from hydrogenated phospholipid whose phosphatidylcholine content is 60 mass% or more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005049757A JP4533185B2 (en) | 2005-02-24 | 2005-02-24 | Solid lipid particle formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005049757A JP4533185B2 (en) | 2005-02-24 | 2005-02-24 | Solid lipid particle formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006232731A JP2006232731A (en) | 2006-09-07 |
JP4533185B2 true JP4533185B2 (en) | 2010-09-01 |
Family
ID=37040784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005049757A Expired - Lifetime JP4533185B2 (en) | 2005-02-24 | 2005-02-24 | Solid lipid particle formulation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4533185B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5555074B2 (en) * | 2010-06-30 | 2014-07-23 | 花王株式会社 | Solid lipid emulsion and topical skin preparation |
JP5710281B2 (en) * | 2011-01-12 | 2015-04-30 | 花王株式会社 | Solid lipid emulsion and topical skin preparation |
CA2887046C (en) * | 2012-10-25 | 2021-08-31 | Nestec S.A. | Encapsulated bitter peptides, methods of encapsulating bitter peptides, and nutritional compositions including encapsulated bitter peptides |
US20160175239A1 (en) * | 2014-12-22 | 2016-06-23 | H R D Corporation | Small particle size renewable triglyceride waxes for use in consumer and industrial applications |
FR3030231B1 (en) * | 2014-12-23 | 2018-08-24 | L'oreal | USE OF A FATTY ACID ESTER FOR MATIFYING THE SKIN AND COMPOSITION COMPRISING SAID ESTER |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05505338A (en) * | 1989-11-13 | 1993-08-12 | サイオス ノバ インコーポレイテッド | Lipospheres for controlled delivery of substances |
JPH05262641A (en) * | 1991-03-25 | 1993-10-12 | Brocades Pharma Bv | Topical preparation containing suspension of solid lipid particle |
JPH06510772A (en) * | 1991-09-18 | 1994-12-01 | メダク・ゲゼルシャフト・ヒューア・クリーニシェ・スペツィアルプレパラーテ・ミット・ベシュレンクター・ハフツング | Pharmaceutical carrier made of solid lipid microparticles (solid lipid nanospheres) |
JP2004269502A (en) * | 2003-02-19 | 2004-09-30 | Kose Corp | Oil in water type emulsion cosmetic |
JP2005053879A (en) * | 2003-08-07 | 2005-03-03 | Kose Corp | Emulsion cosmetic |
-
2005
- 2005-02-24 JP JP2005049757A patent/JP4533185B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05505338A (en) * | 1989-11-13 | 1993-08-12 | サイオス ノバ インコーポレイテッド | Lipospheres for controlled delivery of substances |
JPH05262641A (en) * | 1991-03-25 | 1993-10-12 | Brocades Pharma Bv | Topical preparation containing suspension of solid lipid particle |
JPH06510772A (en) * | 1991-09-18 | 1994-12-01 | メダク・ゲゼルシャフト・ヒューア・クリーニシェ・スペツィアルプレパラーテ・ミット・ベシュレンクター・ハフツング | Pharmaceutical carrier made of solid lipid microparticles (solid lipid nanospheres) |
JP2004269502A (en) * | 2003-02-19 | 2004-09-30 | Kose Corp | Oil in water type emulsion cosmetic |
JP2005053879A (en) * | 2003-08-07 | 2005-03-03 | Kose Corp | Emulsion cosmetic |
Also Published As
Publication number | Publication date |
---|---|
JP2006232731A (en) | 2006-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4963958B2 (en) | Stable concentrated and diluted oil-in-water emulsions, processes for their preparation, and formulation processes using these emulsions | |
KR20110107335A (en) | Production method of O / W microemulsion external preparation | |
JP5491917B2 (en) | Emulsified cosmetics | |
JP6339376B2 (en) | Cosmetics | |
JP7496152B2 (en) | Retinal-containing multilamellar vesicles and cosmetic compositions containing the same | |
JP5710281B2 (en) | Solid lipid emulsion and topical skin preparation | |
MXPA05005720A (en) | Emulsive water-soluble concentrates. | |
JP2013147432A (en) | Emulsion cosmetic | |
JP5833810B2 (en) | Oil-in-water emulsified cosmetic | |
JP4533185B2 (en) | Solid lipid particle formulation | |
JP5778908B2 (en) | Oil-in-water emulsion composition | |
JP2012116783A (en) | Emulsified composition | |
JP7211818B2 (en) | Skin topical agent | |
JP5306675B2 (en) | Sucrose fatty acid ester and emulsifier for oil-in-water emulsion composition | |
JP5555074B2 (en) | Solid lipid emulsion and topical skin preparation | |
JP2014001181A (en) | Emulsified composition | |
JP6850599B2 (en) | Oil-in-water emulsified composition and external preparation for skin | |
WO2014069631A1 (en) | Vesicle composition, and external preparation for skin and cosmetic preparation each of which contains same | |
JP4808445B2 (en) | W / O type emulsion composition | |
JP5306676B2 (en) | Sucrose fatty acid ester and emulsifier for oil-in-water emulsion composition | |
JP3765119B2 (en) | Highly water-containing oil-in-water emulsion composition and method for producing the same | |
JP6640556B2 (en) | Oil-in-water liquid bath agent and method for producing the same | |
JP5576028B2 (en) | Cosmetics | |
JP6748488B2 (en) | Oil-in-water emulsion composition and method for producing the same | |
JP2013129625A (en) | Skin care preparation of water-in-oil type emulsion dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070209 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070725 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20081114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081125 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100309 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100426 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100608 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100611 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 4533185 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130618 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |